## Legacy Novozymes full year 2023

5%
Organic sales growth<sup>1</sup>


25.4%

EBIT margin before special items<sup>1 2</sup>


16.5%

ROIC incl. goodwill before special items<sup>1 2</sup>






EBIT margin




**EBIT** 


## Sales by business area



## Sales by geography



% of sales \* Organic sales growth



<sup>&</sup>lt;sup>1</sup> Audited results will be presented in annual report on February 8.

<sup>&</sup>lt;sup>2</sup> Special items include costs related to proposed combination with Chr. Hansen